Structure Therapeutics Stock
Structure Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Raymond C. Stevens
- Employees
- 281
- Market cap
- $1.2 B
- IPO
- 03/02/2023
Structure Therapeutics Inc. is an international biopharmaceutical company in the biotechnology sector that is currently in its clinical development phase. Headquartered in South San Francisco, USA, the company was established in 2016 and operates under the leadership of CEO Raymond C. Stevens. The company is committed…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Structure Therapeutics stock: price history
1D
-5.0%
1W
-17.5%
1M
-40.6%
6M
-58.5%
YTD
-69.7%
1Y
-23.5%
2Y
-45.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~8% weaker price swings than usual
Ask the agents about Structure Therapeutics
Analyst assessment of Structure Therapeutics
PRICE TARGET LOW
US$70.00
CONSENSUS
US$90.50
MEDIAN
US$90.50
PRICE TARGET HIGH
US$111.00
0
STRONG BUY
14
BUY
0
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 09/09/2026
Structure Therapeutics stock metrics
P/E
-6.96
P/B
1.13
EV/EBITDA
-4.46
RETURN ON EQUITY
-7.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.1%
FLOAT SHARES
54,728,133
AVG. DAILY VOLUME (30D)
1,483,969
Insider transactions (SEC)
Coll Crespo Blas
Coll Crespo Blas
Lin Xichen
Lin Xichen
Lin Xichen
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Structure Therapeutics stock
What does Structure Therapeutics do?
Structure Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Raymond C. Stevens, the company employs around 281 people.
The IPO was on 03/02/2023; the stock trades on NASDAQ under the ticker GPCR.
What do analysts say about Structure Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$90.50, ranging from US$70.00 to US$111.00, with a median of US$90.50.
This is an external assessment, not a statement by Market Jury.
When does Structure Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -8% stronger than usual.
Does Structure Therapeutics pay a dividend?
No, Structure Therapeutics currently does not pay a dividend.
Which stocks are comparable to Structure Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Structure Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Structure Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.